Integrated Filing — IndAS


General information about company

Scrip Code 507789
NSE Symbol JAGSNPHARM
MSEI Symbol NOTLISTED
ISIN INE048B01035
Name of company JAGSONPAL PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 06-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 06-May-2025   17:10:00
End date and time of board meeting 06-May-2025   17:46:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2022-02-11
Indicate Company website link for updated RPT policy of the Company https://www.jagsonpal.com/wp-content/uploads/2024/07/8.-Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable, No default.



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 585600000 2687160000
Other income 27700000 81900000
Total income 613300000 2769060000
2 Expenses
(a) Cost of materials consumed 34850000 183430000
(b) Purchases of stock-in-trade 174970000 802210000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 7380000 -21260000
(d) Employee benefit expense 165680000 709330000
(e) Finance costs 2590000 9580000
(f) Depreciation, depletion and amortisation expense 23050000 81310000
(f) Other Expenses
1 other Expenses 115580000 502740000
Total other expenses 115580000 502740000
Total expenses 524100000 2267340000
3 Total profit before exceptional items and tax 89200000 501720000
4 Exceptional items -2120000 196870000
5 Total profit before tax 87080000 698590000
6 Tax expense
7 Current tax 12390000 135720000
8 Deferred tax 8860000 9260000
9 Total tax expenses 21250000 144980000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 65830000 553610000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 65830000 553610000
17 Other comprehensive income net of taxes -2900000 2190000
18 Total Comprehensive Income for the period 62930000 555800000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 132800000 132800000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 2266700000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.98 8.26
Diluted earnings (loss) per share from continuing operations 0.98 8.22
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.98 8.26
Diluted earnings (loss) per share from continuing and discontinued operations 0.98 8.22
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 6110000
Capital work-in-progress 0
Investment property 0
Goodwill 96930000
Other intangible assets 841500000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 173910000
Total non-current financial assets 173910000
Deferred tax assets (net) 7980000
Other non-current assets 44230000
Total non-current assets 1170660000
2 Current assets
Inventories 152000000
Current financial asset
Current investments 0
Trade receivables, current 131760000
Cash and cash equivalents 112150000
Bank balance other than cash and cash equivalents 1175170000
Loans, current 0
Other current financial assets 670000
Total current financial assets 1419750000
Current tax assets (net) 0
Other current assets 40190000
Total current assets 1611940000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 2782600000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 132800000
Other equity 2266700000
Total equity attributable to owners of parent 2399500000
Non controlling interest
Total equity 2399500000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 86700000
Total non-current financial liabilities 86700000
Provisions, non-current 6660000
Deferred tax liabilities (net) 30700000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 124060000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 14710000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 82630000
Total Trade payable 97340000
Other current financial liabilities 119560000
Total current financial liabilities 216900000
Other current liabilities 32000000
Provisions, current 10140000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 259040000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 383100000
Total equity and liabilites 2782600000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -3880000 2920000
Total Amount of items that will not be reclassified to profit and loss -3880000 2920000
2 Income tax relating to items that will not be reclassified to profit or loss -980000 730000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -2900000 2190000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 698590000
Adjustments for reconcile profit (loss)
Adjustments for finance costs -9580000
Adjustments for decrease (increase) in inventories 10000
Adjustments for decrease (increase) in trade receivables, current -22250000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -7650000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 160000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 21380000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 81310000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 3820000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 44790000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income -76450000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 68040000
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) -184560000
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -64160000
Net cash flows from (used in) operations 634430000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 81430000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 553000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 357180000
Purchase of property, plant and equipment 3480000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets -883570000
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 78400000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -451470000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 0
Interest paid 1000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -115980000
Net cash flows from (used in) financing activities -116980000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -15450000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -15450000
Cash and cash equivalents cash flow statement at beginning of period 127600000
Cash and cash equivalents cash flow statement at end of period 112150000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s Walker Chandiok & Co LLP, Chartered Accountants Yes 31-May-2025


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Jagsonpal Pharmaceuticals Limited Naari Pharma Pvt Ltd Enterprises in which certain directors are intrested or are in common Purchase of goods or services 830000 Approve 830000 0 0
2 Jagsonpal Pharmaceuticals Limited Naari Pharma Pvt Ltd Enterprises in which certain directors are intrested or are in common Sale of goods or services 1200000 Approve 1200000 0 0
3 Jagsonpal Pharmaceuticals Limited Aresko Life Science Private Limited Enterprises in which certain directors are intrested or are in common Sale of goods or services 120000 Approve 120000 0 0
4 Jagsonpal Pharmaceuticals Limited Aresko Life Science Private Limited Enterprises in which certain directors are intrested or are in common Purchase of goods or services 12500000 Approve 12500000 0 0
5 Jagsonpal Pharmaceuticals Limited Ashish Lakhotia Chief Financial Officer Remuneration 1930000 Approve 1930000 0 0
6 Jagsonpal Pharmaceuticals Limited Abhishek Joshi Company Secretary Remuneration 540000 Approve 540000 0 0
7 Jagsonpal Pharmaceuticals Limited Manish Gupta Managing Director Remuneration 46880000 Approve 46880000 0 0
8 Jagsonpal Pharmaceuticals Limited Sachin Jain Chief Financial Officer Remuneration 850000 Approve 850000 0 0
9 Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary Remuneration 70000 Approve 70000 0 0
10 Jagsonpal Pharmaceuticals Limited Debasis Bikas Nandy Independent Director Any other transaction Sitting Fees 500000 Approve 500000 0 0
11 Jagsonpal Pharmaceuticals Limited Radhika Madhukar Dudhat Independent Director Any other transaction Sitting Fees 380000 Approve 380000 0 0
12 Jagsonpal Pharmaceuticals Limited Pallavi Dinodia Gupta Independent Director Any other transaction Sitting Fees 450000 Approve 450000 0 0
13 Jagsonpal Pharmaceuticals Limited Rajpal Singh Kochhar Promoter Sale of fixed assets 1600000 Approve 1600000 0 0
Total value of transaction during the reporting period 67850000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt